Douglas Williams

Douglas Williams

Chief Executive Officer at CODIAK BIOSCIENCES

Net worth: 10 929 $ as of 30/06/2026

67 year
Health Technology
Finance
Consumer Services

Profile

Douglas E.
Williams
is President & Chief Executive Officer at Codiak BioSciences, Inc. since 2015.
He is Chief Executive Officer at TriArm Therapeutics (Taiwan) Ltd. and Triarm Therapeutics Ltd. starting in 2024.
He serves as Chairman at Xenikos BV, Climb Bio, Inc. (since 2024), and CAMP4 Therapeutics Corp.
(starting 2025).
He is Director at eGenesis, Inc., Cygnal Therapeutics, Inc., Cytoimmune Therapeutics, Inc. (since 2021), Panacea Acquisition Corp.
II (since 2021), and Stablix, Inc. (since 2023).
Former roles include Chief Executive Officer & Director at ZymoGenetics, Inc. (2009–2010), Director, Chief Technology Officer & Executive VP at Immunex Corp.
(1988–2002), Director at Array BioPharma, Inc. (2004–2011), Director, Chief Scientific Officer, EVP-R&D at Seagen, Inc. (2002–2005), Director at Anadys Pharmaceuticals, Inc. (2004–2009), Independent Director at Ironwood Pharmaceuticals, Inc. (2014–2019), Director at Aerovance, Inc., Independent Director at Cascadian Therapeutics LLC (2011–2013), Independent Director at Ovid Therapeutics, Inc. (2016–2021), Independent Non-Executive Director at AC Immune SA (2018–2025), Director at Regulus Therapeutics, Inc. (2012–2017), Senior Vice President at Amgen, Inc. (2002–2003), Executive Vice President-Research & Development at Biogen, Inc. (2011–2015), Head-Health & Strategic Development at Genesis Research & Development Corp.
Ltd. (2002–2003), Executive Vice President at Biogen Idec New Ventures, Inc., Secretary & Trustee at Fred Hutchinson Cancer Research Center, and Executive VP, President-Research & Development at Sana Biotechnology, Inc. (2023–2024).
Education includes a doctorate from State University of New York at Buffalo, and undergraduate degrees from the University of Massachusetts Lowell and The Indiana University School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
10/06/2026 2,501 ( 0.01% ) 10 929 $ 30/06/2026
05/06/2026 0 ( -.--% ) - $ 30/06/2026

Douglas Williams active positions

CompaniesPositionStart
CODIAK BIOSCIENCES Chief Executive Officer 01/08/2015
PANACEA ACQUISITION CORP. II Director/Board Member 06/04/2021
HUMORIGIN BIOTECHNOLOGY CORP Chief Executive Officer 09/09/2024
CLIMB BIO, INC. Chairman 11/11/2024
CAMP4 THERAPEUTICS CORPORATION Chairman 10/09/2025
Director/Board Member -
Chief Executive Officer 09/09/2024
Director/Board Member 18/01/2023
Director/Board Member 15/06/2021
░░░░░░░ ░░ ░░░░░░░░ -

Former positions of Douglas Williams

CompaniesPositionEnd
░░ ░░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
See the detail of Douglas Williams's experience

Training of Douglas Williams

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

75

1st degree connections

31

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies31

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Finance

Commercial Services

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

  1. Stock Market
  2. Insiders
  3. Douglas Williams